Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

Mortality benefit of implantable cardioverter-defibrillator therapy in patients with persistent malignant ventricular arrhythmias despite amiodarone treatment.

Barron HV, Khan HH, Viskin S, Heller K, Kalman JM, Scheinman MM, Lesh MD.

Am J Cardiol. 1997 May 1;79(9):1180-4.

PMID:
9164881
2.

Improved survival of cardiac transplantation candidates with implantable cardioverter defibrillator therapy: role of beta-blocker or amiodarone treatment.

Ermis C, Zadeii G, Zhu AX, Fabian W, Collins J, Lurie KG, Sakaguchi S, Benditt DG.

J Cardiovasc Electrophysiol. 2003 Jun;14(6):578-83.

PMID:
12875416
3.

Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators.

Ho AT, Pai SM, Timothy P, Pai RG.

Pacing Clin Electrophysiol. 2005 Jul;28(7):647-53.

PMID:
16008799
4.
5.

Patients at lower risk of arrhythmia recurrence: a subgroup in whom implantable defibrillators may not offer benefit. Antiarrhythmics Versus Implantable Defibrillator (AVID) Trial Investigators.

Hallstrom AP, McAnulty JH, Wilkoff BL, Follmann D, Raitt MH, Carlson MD, Gillis AM, Shih HT, Powell JL, Duff H, Halperin BD; Antiarrhythmics Versus Implantable Defibrillator (AVID) Trial Investigators.

J Am Coll Cardiol. 2001 Mar 15;37(4):1093-9.

6.

[14-year experience with implantable cardioverter/defibrillators: determination of prognosis and discharge behavior].

Vester EG, Dees H, Dobran I, Hennersdorf M, Perings C, Heydthausen M, Winter J, Strauer BE.

Z Kardiol. 2000;89 Suppl 3:194-205. German.

PMID:
10810803
9.

Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.

Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, Greene HL, Boczor S, Domanski M, Follmann D, Gent M, Roberts RS.

Eur Heart J. 2000 Dec;21(24):2071-8.

PMID:
11102258
10.
11.

Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction.

Sanders GD, Hlatky MA, Every NR, McDonald KM, Heidenreich PA, Parsons LS, Owens DK.

Ann Intern Med. 2001 Nov 20;135(10):870-83.

PMID:
11712877
12.

Clinical usefulness of electrophysiologic testing in patients with ventricular tachycardia and chronic chagasic cardiomyopathy treated with amiodarone or sotalol.

Leite LR, Fenelon G, Simoes A Jr, Silva GG, Friedman PA, de Paola AA.

J Cardiovasc Electrophysiol. 2003 Jun;14(6):567-73.

PMID:
12875414
13.
14.

Appropriate ICD therapy in patients with idiopathic dilated cardiomyopathy: long term follow-up.

Karaoguz R, Maydanozcu S, Altun T, Güldal M, Akyürek O, Erol C.

Int Heart J. 2006 Sep;47(5):763-73.

16.
17.
18.

Amiodarone versus Implantable Defibrillator (AMIOVIRT): background, rationale, design, methods, results and implications.

Wijetunga M, Strickberger SA; Amiodarone Versus Implantable Defibrillator Randomized Trial.

Card Electrophysiol Rev. 2003 Dec;7(4):452-6.

PMID:
15071274
19.

Long-term follow-up of patients requiring intravenous amiodarone to suppress hemodynamically destabilizing ventricular arrhythmias.

Fogel RI, Herre JM, Kopelman HA, Kowey PR, Trohman RG, Fineberg N, Prystowsky EN.

Am Heart J. 2000 Apr;139(4):690-5.

PMID:
10740153

Supplemental Content

Support Center